Press releases

Advanced Search
  • Aug 4, 2014
    Total Nucleic Acid Reagents Now Available Worldwide - Streamlined Workflow for In-House Developed Assays

    BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson, and Company) (NYSE: BDX), announced today the availability of the Total Nucleic Acid (TNA) suite of...

  • Jul 31, 2014
    ChloraPrep 1 mL Applicator Provides Additional Option to Proven Portfolio of Patient Skin Preparation Products

    SAN DIEGO, July 31, 2014 /PRNewswire/ – CareFusion (NYSE:CFN), a leading global medical technology company, today announced the launch of its ChloraPrep® 1 mL applicator, the newest addition to...

  • Jul 31, 2014
    - Announces revenues of $2.157 billion, an increase of 5.1 percent, or 4.6 percent on a foreign currency-neutral basis.

    BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for the third fiscal quarter ended June 30, 2014,...

  • Jul 28, 2014
    Assays bring an innovative solution to microbiology and molecular labs

    BD Diagnostics, a segment of BD (Becton, Dickinson and Company), (NYSE: BDX) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for the BD ProbeTec(TM)...

  • Jul 22, 2014

    The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 54.5 cents per common share payable on September 30, 2014 to holders of record on...